List of Excipients in Branded Drug BELEODAQ

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Acrotech Biopharma LLC	BELEODAQ	belinostat	68152-108	ARGININE	2027-10-27
Acrotech Biopharma Inc	BELEODAQ	belinostat	72893-002	ARGININE	2027-10-27

Beleodaq Excipient Strategy and Commercial Opportunities for Belinostat

Last updated: August 11, 2026

Beleodaq is an intravenous, lyophilized belinostat product with a simple excipient system of L-arginine and histidine. The main commercial opportunity is not a novel excipient claim. It is an improved injectable presentation that reduces reconstitution steps, minimizes vial waste, improves dose preparation, and supports generic or 505(b)(2) competition in relapsed or refractory peripheral T-cell lymphoma (PTCL).

What is Beleodaq and how is it administered?

Beleodaq contains belinostat, a histone deacetylase inhibitor approved for adults with relapsed or refractory PTCL after prior systemic therapy. The FDA granted accelerated approval in July 2014 based on response-rate data under the accelerated approval pathway [1].

The approved regimen is:

Product attribute	Beleodaq specification
Active ingredient	Belinostat
Dosage form	Lyophilized powder for intravenous infusion
Strength	500 mg per single-dose vial
Route	Intravenous infusion
Dose	1,000 mg/m² on Days 1 through 5 of a 21-day cycle
Reconstitution	Sterile Water for Injection
Diluent	0.9% Sodium Chloride Injection
Infusion time	30 minutes
Primary excipients	L-arginine and histidine
FDA approval	July 3, 2014
Initial sponsor	Spectrum Pharmaceuticals
Current commercial context	Specialty oncology product with limited-volume hospital use

The high-dose, multi-day schedule creates recurring demand for drug preparation, pharmacy labor and injectable packaging. A typical patient may require more than two 500 mg vials per treatment day, depending on body-surface area. The commercial value of an improved formulation therefore depends heavily on dose efficiency and preparation convenience.

What excipients are used in Beleodaq?

Each 500 mg vial contains belinostat with L-arginine and histidine. The product is reconstituted before dilution into normal saline for infusion [2].

Excipient function

Excipient	Likely formulation role	Commercial relevance
L-arginine	Solubilization and pH control; may support chemical stability of belinostat	Can be retained in follow-on products, but is unlikely to provide strong standalone IP
Histidine	Buffering and pH control	Common injectable buffer with established regulatory precedent
Sterile Water for Injection	Reconstitution vehicle	Creates an additional preparation step and handling requirement
0.9% Sodium Chloride Injection	Final infusion diluent	Limits ready-to-use commercialization unless bag stability is established

The excipient system is relatively conventional. L-arginine and histidine are widely used in parenteral products and have broad regulatory familiarity. A competitor would likely obtain greater commercial value from concentration, container closure, reconstitution and stability improvements than from replacing either excipient.

What formulation patents protect Beleodaq?

Publicly available product information identifies the formulation composition but does not establish that the commercial opportunity depends on a broad, active patent claim covering L-arginine and histidine themselves. Those excipients are established pharmaceutical materials and generally offer weak composition-of-matter protection.

Potentially valuable formulation claims could cover:

• Specific belinostat-to-L-arginine ratios
• Histidine concentration and pH ranges
• Lyophilization cycle parameters
• Residual moisture limits
• Reconstitution time
• Reconstituted-solution stability
• Diluted-solution stability in saline
• Protection from oxidation, hydrolysis or precipitation
• Container-closure systems
• Ready-to-use or ready-to-dilute presentations
• Low-volume or high-concentration formulations
• Compatibility with infusion bags and administration sets

The strongest defensible formulation estate would combine composition, process and performance limitations. A claim limited only to the presence of L-arginine and histidine would face substantial validity and obviousness pressure because both excipients are conventional in injectable formulation development.

What manufacturing and IP barriers exist?

The principal barriers are technical rather than raw-material barriers. A follow-on developer must demonstrate:

1. Reproducible belinostat content and impurity control.
2. Adequate lyophilized-cake quality.
3. Fast and complete reconstitution.
4. Chemical stability after reconstitution.
5. Compatibility with saline and infusion equipment.
6. Sterility assurance and particulate control.
7. Consistent delivery across the labeled concentration range.
8. Control of vial adsorption and extractables.
9. A validated manufacturing process for a potentially small annual volume.

Belinostat has a multi-day dosing schedule and may be handled under oncology pharmacy conditions. Any formulation that reduces manipulations without compromising stability can create value even if the underlying excipients are not novel.

What commercial opportunities exist for Beleodaq excipient reformulation?

The best opportunities are differentiated injectable presentations.

Ready-to-use or ready-to-dilute belinostat

A liquid concentrate could eliminate lyophilized-vial reconstitution. The product would need sufficient shelf life, low impurity formation and acceptable container compatibility. A ready-to-dilute product could be positioned for hospitals seeking lower preparation time and fewer reconstitution errors.

The major technical risk is belinostat stability at the required concentration. A liquid product also increases sensitivity to oxidation, hydrolysis, light exposure and container-closure interactions.

Higher-concentration formulation

A higher-concentration presentation could reduce infusion volume and vial count. This may be attractive for patients with fluid restrictions and for institutions seeking smaller preparation volumes.

The formulation must avoid precipitation after dilution. It would also need to demonstrate acceptable viscosity, syringeability, particulate control and compatibility with standard infusion systems.

Dual-chamber vial or reconstitution device

A dual-chamber container could separate the belinostat cake from the reconstitution liquid until administration. This approach could preserve solid-state stability while reducing preparation steps.

The disadvantages are higher packaging cost, device-development requirements and more complex regulatory review. The opportunity is strongest if a conventional liquid formulation cannot achieve adequate shelf life.

Alternative vial fill size

The 500 mg vial may create waste because the dose is based on body-surface area and administered for five consecutive days. A 1,000 mg vial could reduce vial use for larger patients, while a smaller vial could reduce waste for lower body-surface-area patients.

A multi-size portfolio could improve dose efficiency but would increase manufacturing complexity. The commercial case depends on actual patient-size distribution, vial-overfill requirements and hospital purchasing behavior.

Premixed infusion bag

A premixed bag would offer the greatest preparation convenience. It would also carry the highest stability and distribution burden. The product would need to remain stable through shipping, storage, handling and the full in-use period.

A premixed product may be more suitable for institutional channels than for retail distribution because belinostat is administered in oncology centers and hospitals.

Lyophilized formulation with faster reconstitution

The lowest-risk reformulation may be an improved lyophilized product that preserves the current solid-state approach while reducing reconstitution time. Changes could include:

• Optimized cake porosity
• Reduced residual moisture
• Improved vial fill geometry
• Modified excipient concentration
• Controlled pH after reconstitution
• More efficient reconstitution instructions
• Lower extractable and particulate burden

This strategy may support a 505(b)(2) product or an ANDA, depending on the final formulation and the extent of clinical or comparative data required.

How does Beleodaq compare with competing PTCL therapies?

Belinostat competes with other systemic treatments for relapsed or refractory PTCL, including romidepsin, pralatrexate, brentuximab vedotin in appropriate CD30-positive disease, and combination regimens. The relevant commercial comparison is not limited to mechanism. Route, schedule, monitoring, infusion burden and formulation convenience influence treatment selection.

Product	Active ingredient	Route	Formulation profile	Commercial implication
Beleodaq	Belinostat	IV infusion	Lyophilized vial; reconstitution and dilution required	Opportunity to reduce pharmacy labor and preparation waste
Istodax	Romidepsin	IV infusion	Reconstitution and dilution requirements	Competes in the HDAC inhibitor segment
Folotyn	Pralatrexate	IV administration	Injectable solution	Lower formulation complexity but different toxicity and dosing profile
Adcetris	Brentuximab vedotin	IV infusion	Antibody-drug conjugate	Stronger biologic manufacturing and IP barriers; restricted by CD30 status

Belinostat has no biosimilar pathway because it is a small-molecule drug. The relevant competitive threats are generics, 505(b)(2) products, therapeutic substitutes and new PTCL regimens.

When does Beleodaq lose exclusivity?

Beleodaq's principal regulatory exclusivity was limited by the orphan-drug framework. FDA granted seven years of orphan exclusivity for the approved PTCL indication, running from the July 2014 approval date [1].

Exclusivity category	Beleodaq status
Orphan-drug exclusivity	Began July 3, 2014; generally extended through July 3, 2021 for the approved indication
New chemical entity exclusivity	Five years from approval, subject to statutory exceptions
Patent exclusivity	Depends on issued patents, term adjustments, terminal disclaimers and Orange Book listings
Pediatric exclusivity	No extension should be assumed without a specific FDA grant
Biosimilar exclusivity	Not applicable
Generic pathway	ANDA or 505(b)(2), subject to applicable patents and regulatory requirements

Orphan exclusivity blocks FDA approval of the same drug for the same disease or condition by another sponsor during the exclusivity period. It does not prevent all products containing belinostat from entering the market for every possible use.

The commercial relevance of any remaining patent depends on whether the claims cover belinostat itself, a formulation, a method of treatment or a manufacturing process. A generic developer can avoid some method-of-use claims through a section viii statement or labeling strategy if the relevant indication can be carved out.

What is the Orange Book status of Beleodaq?

The Orange Book is the controlling FDA source for approved patents and exclusivity listings associated with approved drug products [3]. Beleodaq's commercial patent risk should be assessed by reviewing:

• Current product and sponsor listings
• Active patent numbers
• Patent expiration dates
• Use codes
• Paragraph IV certification history
• Any 30-month litigation stays
• Patent delistings or administrative changes

Formulation developers should not treat the absence of a broad formulation patent as proof of freedom to operate. A belinostat product may still implicate compound, salt, crystalline-form, process or method-of-use patents outside a narrow excipient analysis.

Which companies are challenging Beleodaq exclusivity?

No specific Paragraph IV challenger should be treated as commercially active without a current FDA Orange Book review and corresponding litigation docket. Generic entry analysis should distinguish between:

• A filed ANDA with a Paragraph IV certification
• A patent challenge described in a company filing
• A patent lawsuit under the Hatch-Waxman Act
• A commercial launch
• A tentative approval
• A product listed in FDA's approved drug databases

For an injectable oncology product with a relatively small market, the economic incentive to file may be lower than for a high-volume oral medicine. A challenger may nevertheless pursue entry if it can use a simple formulation, obtain hospital contracts or combine the product with a broader oncology portfolio.

What generic launch risks exist for Beleodaq?

The most credible launch scenarios are:

Scenario 1: Conventional generic vial

A competitor reproduces the 500 mg lyophilized vial with the same or similar excipients. This is the lowest technical-risk path. Price competition would be the main commercial effect.

Scenario 2: 505(b)(2) improved injectable

A sponsor introduces a faster-reconstituting, higher-concentration or ready-to-dilute product. This route may support differentiated labeling and hospital value propositions but can require comparative clinical or bridging evidence.

Scenario 3: Authorized or licensed generic

A branded or specialty-pharma partner licenses an existing manufacturing platform. This could accelerate entry and provide supply reliability, but the addressable market may not support extensive price discounting.

Scenario 4: Therapeutic substitution

A new PTCL therapy reduces demand for belinostat without directly challenging its patents. This is a clinical and commercial risk rather than a Hatch-Waxman event.

How strong is the patent estate for an excipient-based Beleodaq product?

The excipient-related patent estate is likely moderate to weak if it relies only on L-arginine and histidine. Patent strength would improve materially if the claims require a defined combination of:

• Belinostat concentration
• Excipient ratio
• Narrow pH range
• Lyophilization parameters
• Stability threshold
• Reconstitution time
• Dilution compatibility
• Specific container or delivery system

Performance-based formulation claims can be valuable because they connect the composition to a measurable clinical or manufacturing benefit. They also face challenges if the result would have been expected from routine formulation screening.

A commercially useful patent portfolio should include separate families for the formulation, manufacturing process, container closure, administration system and treatment method. Geographic coverage should prioritize the United States, European Patent Convention countries, Japan, Canada, Australia and major oncology markets. China and India may be important manufacturing and supply-chain jurisdictions.

What licensing deals could support a Beleodaq reformulation?

Potential deal structures include:

Structure	Strategic use
Formulation license	Grants an established oncology company rights to a ready-to-use or improved lyophilized product
Manufacturing license	Transfers a validated sterile-fill or lyophilization process
Co-development agreement	Shares development cost and commercial risk
Regional license	Allocates rights by geography where hospital demand differs
Supply agreement	Provides drug product or excipient-enabled intermediate to a marketing partner
Authorized generic agreement	Supports rapid entry with lower commercial investment

The most attractive partner would likely have sterile injectable capacity, hospital oncology distribution and experience with FDA post-approval changes. A company with only oral solid-dose capabilities would face a substantial technology gap.

What FDA regulatory pathway applies to a new Beleodaq formulation?

A conventional generic may use the ANDA pathway if it can establish pharmaceutical equivalence and bioequivalence under FDA requirements. An improved formulation with a new concentration, delivery system, excipient profile or dosing presentation may require a 505(b)(2) application [4].

Key regulatory issues include:

• Injectable product quality and sterility
• Comparative impurity profiles
• Reconstitution and dilution instructions
• In-use stability
• Container-closure integrity
• Particulate matter
• Extractables and leachables
• Compatibility with infusion materials
• Drug-drug and solution compatibility
• Labeling differences
• Clinical bridging for meaningful formulation changes

A reformulation that changes only inactive ingredients may still require extensive chemistry, manufacturing and controls data. The regulatory burden rises when the change affects concentration, exposure, administration time or dosing convenience.

What is the revenue exposure and market opportunity?

Beleodaq is a specialty oncology product rather than a mass-market drug. Revenue exposure is concentrated in:

• Relapsed or refractory PTCL patients
• Hospital and outpatient infusion centers
• Oncology group purchasing organizations
• Specialty distributors
• Markets with reimbursement for branded or specialty injectables

The formulation opportunity is therefore measured less by broad patient volume and more by value per treatment cycle. A product that reduces vial waste, preparation time and medication errors can compete even with a modest patient population.

The highest-value commercial attributes are:

1. Lower total cost per administered dose.
2. Reduced vial wastage.
3. Fewer preparation steps.
4. Longer post-reconstitution stability.
5. Lower infusion volume.
6. Reliable sterile supply.
7. Simplified hospital inventory management.

Key Takeaways

• Beleodaq is a 500 mg lyophilized belinostat vial for intravenous infusion.
• The labeled excipients are L-arginine and histidine.
• The excipients are conventional and unlikely to support strong protection by themselves.
• The strongest commercial opportunity is an improved injectable presentation.
• Ready-to-dilute, higher-concentration, dual-chamber and faster-reconstituting products are the leading formulation concepts.
• The principal competitive pathway is generic or 505(b)(2) entry, not biosimilar competition.
• Orphan exclusivity began in 2014 and generally ended in 2021; current patent risk requires Orange Book and litigation review.
• Dose-based vial waste and five consecutive infusion days create a clear hospital-efficiency opportunity.
• A durable patent estate should cover composition, process, stability, packaging and administration technology.
• Commercial success depends on hospital economics and manufacturing reliability as much as on excipient novelty.

FAQs

Can L-arginine and histidine be replaced in a generic Beleodaq formulation?

Yes, replacement may be possible if the alternative formulation meets applicable injectable-product requirements and demonstrates equivalent quality, stability and performance. The regulatory pathway may be more complex than a product using the same inactive ingredients.

Is a ready-to-use liquid belinostat product commercially attractive?

Potentially. It could eliminate reconstitution and reduce pharmacy labor, but liquid stability, container compatibility and shelf-life requirements may make development more difficult than an improved lyophilized vial.

Does Beleodaq have biosimilar risk?

No. Belinostat is a small-molecule drug. Competitive entry would occur through generic, 505(b)(2), licensing or therapeutic-substitution pathways.

Can a smaller vial reduce Beleodaq drug waste?

Yes. A vial-size portfolio could better match body-surface-area dosing and reduce discarded drug. The benefit must be balanced against added packaging, validation and inventory costs.

Which formulation attribute is most valuable to hospitals?

Dose efficiency is likely the strongest economic driver, followed by reduced preparation time and longer post-reconstitution stability. A smaller infusion volume can also matter for patients with fluid-management constraints.

References

1. U.S. Food and Drug Administration. (2014). FDA approves Beleodaq for treatment of peripheral T-cell lymphoma. https://www.fda.gov
2. U.S. Food and Drug Administration. (2024). Beleodaq (belinostat) for injection: Prescribing information. https://www.accessdata.fda.gov
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov
4. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). https://www.fda.gov